
News|Articles|November 1, 2002
HMG CoA reductase inhibitor-induced muscle toxicity: risks, monitoring, and management (PDF)
Although the commonly used HMG CoA reductase inhibitors (statins) are well tolerated and relatively safe, muscle toxicity and rhabdomyolysis can occur with administration and can be severe. This risk is higher with more bioavailable and lipophilic statins. This article summarizes what is known about the etiology of statin-associated muscle toxicity, the risks for each statin, and the current recommendations for monitoring and management.
Advertisement
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
The FDA proposes ditching comparative efficacy studies for biosimilars
2
UC Davis develops new drug for bladder cancer patients
3
Phase 3 trial launches for novel antibody targeting integrin beta-6 in advanced lung cancer
4
How new psoriasis, alopecia and atopic dermatitis therapies stood out at Fall Clinical Derm 2025
5




















































